N
ACRV icon

Nuveen’s Acrivon Therapeutics ACRV Stock Holding History

Nuveen’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,402
Closed -$27.2K – 3276
2025
Q1 		$27.2K Hold
13,402
– – ﹤0.01% 3274
2024
Q4 		$80.7K Sell
13,402
-12,377
-48% -$89.9K ﹤0.01% 3302
2024
Q3 		$180K Buy
25,779
+13,958
+118% +$110K ﹤0.01% 3243
2024
Q2 		$68.6K Hold
11,821
– – ﹤0.01% 3316
2024
Q1 		$84.5K Hold
11,821
– – ﹤0.01% 3255
2023
Q4 		$58.2K Hold
11,821
– – ﹤0.01% 3303
2023
Q3 		$113K Hold
11,821
– – ﹤0.01% 3115
2023
Q2 		$153K Buy
+11,821
New +$143K ﹤0.01% 3130

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Nuveen's ACRV Position: Q2 2025 in Review

Nuveen sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 13,402 shares — an estimated $27.2K sold.

Nuveen first reported a position in ACRV in Q2 2023 and held it in 8 quarters. The position peaked at $180K in Q3 2024. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

  • Nuveen reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 13,402 Acrivon Therapeutics shares in Q2 2025, an estimated $27.2K.
  • Nuveen first reported a position in Acrivon Therapeutics in Q2 2023 and held it in 8 quarters.
  • Nuveen's Acrivon Therapeutics position peaked at $180K in Q3 2024.
  • 53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.